CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world. CryoHoldco is now seven times larger than any other stem cell bank in Latin America with over 275,000 stem cell units in storage.
DRESDEN, Germany, June 28, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, has received a grant from the State Bank of Saxony for the development of microcarriers designed for xeno-free induced pluripotent stem cell culture. The outlook for the technology is for applications in iPSC banking, allogenic therapies, as well as the clean meat industry.
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies. The deal will enable Catalent to offer the building blocks to scale iPSC-based cell therapies while reducing barriers to entry to the clinic for therapeutic companies and is expected to close before the end of 2021, subject to customary conditions. Financial details of the transaction have not been disclosed.
TreeFrog Therapeutics announces the results of two runs of hiPSC amplification in 10L bioreactors at the Annual Meeting of the International Society for Stem Cell Research.
BORDEAUX, France, Jun. 21, 2021 — Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR). The data shows the output from two batches with indistinguishable expansion curves, demonstrating a high degree of reproducibility, while cell analysis showed conservation of stem cell quality. [Read more…]
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
Partnership Follows Kite’s Investment in Shoreline’s Recent Series A Financing
June 17, 2021, SANTA MONICA, Calif. & SAN DIEGO — Kite, a Gilead Company (Nasdaq: GILD), and Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced a strategic partnership to develop novel cell therapies across a variety of cancer targets. [Read more…]